ANBL1531: A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Grant

Date/time Interval

  • March 20, 2019 - March 19, 2024

    • Awarded By

    Total Award Amount

  • 22000.00

    • Direct Costs

  • 18333.00

    • Sponsor Award Id

    • Contributor

  • Matthew Kutny M.D.   Principal Investigator